13 pending office actions
| App # | Title | Examiner | Art Unit | Status | Filed |
|---|---|---|---|---|---|
| 18563058 | TREATMENT METHODS FOR SUBJECTS WITH CANCER HAVING AN ABERRATION IN EGFR AND/OR HER2 | FETTEROLF, BRANDON J | 1626 | Non-Final OA | Nov 21, 2023 |
| 18263613 | TREATING CANCER IN PATIENT WITH PTEN INACTIVATING MUTATION | WHITE, DAWANNA SHAR-DAY | 1627 | Non-Final OA | Jul 31, 2023 |
| 18253521 | Crystalline Forms of 4-amino-N-[4-(methoxymethyl)phenyl]-7-(1-methylcyclopropyl)-6-(3-morpholinoprop-1-yn-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide, Methods of Preparation, and uses Thereof | FETTEROLF, BRANDON J | 1626 | Final Rejection | May 18, 2023 |
| 18026515 | METHODS OF TREATING RIBONUCLEOTIDE REDUCTASE-RELATED DISEASES WITH A RIBONUCLEOTIDE REDUCTASE INHIBITOR | RODRIGUEZ, RAYNA B | 1628 | Final Rejection | Mar 15, 2023 |
| 18044236 | TREATMENT REGIMENS FOR EXON-20 INSERTION MUTANT EGFR CANCERS | ROBINSON, MIKHAIL O'DONNEL | 1627 | Non-Final OA | Mar 07, 2023 |
| 18016103 | EGFR INHIBITOR | NESTOR, DONNA MICHELLE | 1627 | Final Rejection | Jan 13, 2023 |
| 17917765 | CANCER THERAPY USING 3,5-DISUBSTITUTED BENZENE ALKYNYL COMPOUND AND MEK INHIBITOR | HAVLIN, ROBERT H | 1626 | Final Rejection | Oct 07, 2022 |
| 17786504 | THERAPEUTIC AGENT CONTAINING FUSED PYRIMIDINE COMPOUND AS ACTIVE INGREDIENT | WILLIS, DOUGLAS M | 1624 | Final Rejection | Jun 16, 2022 |
| 17633128 | COMBINATION THERAPY FOR CANCER USING AZABICYCLIC COMPOUND AND POLY(ADENOSINE 5'-DIPHOSPHATE-RIBOSE) POLYMERASE INHIBITOR | REILLY, SOPHIA JANE | 1627 | Final Rejection | Feb 04, 2022 |
| 17434655 | CANCER THERAPY USING 3,5-DISUBSTITUTED BENZENE ALKYNYL COMPOUND AND PEMBROLIZUMAB | SKOKO III, JOHN JOSEPH | 1643 | Non-Final OA | Aug 27, 2021 |
| 17434573 | CANCER THERAPY USING 3,5-DISUBSTITUTED BENZENE ALKYNYL COMPOUND AND IMMUNE CHECKPOINT INHIBITOR | CANELLA, KAREN A | 1643 | Final Rejection | Aug 27, 2021 |
| 17432158 | PHARMACEUTICAL COMPOSITION AND THERAPEUTIC METHOD FOR TREATING FGFR1 VARIANT-POSITIVE BRAIN TUMOR | COPPINS, JANET L | 1628 | Non-Final OA | Aug 19, 2021 |
| 16627146 | CHEMOTHERAPY FOR CANCER USING AZABICYCLO COMPOUND | MCKOY, QUINCY ANDRE | 1626 | Final Rejection | Dec 27, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial